PL2793929T3 - Podłoże kondycjonowane uzyskane z łożyskowych mezenchymalnych komórek macierzystych w terapii stanu przedrzucawkowego - Google Patents

Podłoże kondycjonowane uzyskane z łożyskowych mezenchymalnych komórek macierzystych w terapii stanu przedrzucawkowego

Info

Publication number
PL2793929T3
PL2793929T3 PL12824720T PL12824720T PL2793929T3 PL 2793929 T3 PL2793929 T3 PL 2793929T3 PL 12824720 T PL12824720 T PL 12824720T PL 12824720 T PL12824720 T PL 12824720T PL 2793929 T3 PL2793929 T3 PL 2793929T3
Authority
PL
Poland
Prior art keywords
preeclampsia
stem cells
mesenchymal stem
therapeutic treatment
conditioned medium
Prior art date
Application number
PL12824720T
Other languages
English (en)
Inventor
Alessandro Rolfo
Tullia Todros
Original Assignee
Corion Biotech S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corion Biotech S.R.L. filed Critical Corion Biotech S.R.L.
Publication of PL2793929T3 publication Critical patent/PL2793929T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
PL12824720T 2011-12-21 2012-12-21 Podłoże kondycjonowane uzyskane z łożyskowych mezenchymalnych komórek macierzystych w terapii stanu przedrzucawkowego PL2793929T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001183A ITTO20111183A1 (it) 2011-12-21 2011-12-21 Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia

Publications (1)

Publication Number Publication Date
PL2793929T3 true PL2793929T3 (pl) 2017-03-31

Family

ID=45571748

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12824720T PL2793929T3 (pl) 2011-12-21 2012-12-21 Podłoże kondycjonowane uzyskane z łożyskowych mezenchymalnych komórek macierzystych w terapii stanu przedrzucawkowego

Country Status (13)

Country Link
US (2) US20150017122A1 (pl)
EP (1) EP2793929B1 (pl)
JP (1) JP2015502977A (pl)
CA (1) CA2859768C (pl)
DK (1) DK2793929T3 (pl)
ES (1) ES2606297T3 (pl)
HR (1) HRP20161601T1 (pl)
HU (1) HUE032489T2 (pl)
IT (1) ITTO20111183A1 (pl)
PL (1) PL2793929T3 (pl)
PT (1) PT2793929T (pl)
SI (1) SI2793929T1 (pl)
WO (1) WO2013093878A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882687A1 (en) * 2012-09-04 2014-03-13 Pluristem Ltd. Methods for prevention and treatment of preeclampsia
ITTO20120859A1 (it) 2012-10-02 2014-04-03 Univ Degli Studi Torino Nuova applicazione terapeutica di un mezzo condizionato da cellule staminali mesenchimali placentari
GB201314452D0 (en) * 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
WO2015023901A1 (en) * 2013-08-15 2015-02-19 The Regents Of The University Of California Placenta-derived multipotent stem cells
JP6474549B2 (ja) * 2014-03-03 2019-02-27 国立大学法人徳島大学 幹細胞の培養産物の評価指標及びその利用
US20170080030A1 (en) * 2014-03-17 2017-03-23 University Of Virginia Patent Foundation Compositions and methods for treating retinopathy
CN113817672A (zh) 2014-05-18 2021-12-21 儿童医学中心公司 涉及外排体的方法和组合物
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2017123312A2 (en) * 2015-09-02 2017-07-20 Regeneration Worldwide Company, Inc. Composition and methods of using umbilical cord lining stem cells
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
CN110402146A (zh) * 2016-11-03 2019-11-01 埃克森蒂姆生物技术公司 间充质干细胞群、其产物及其用途
CA3046078A1 (en) * 2016-12-05 2018-06-14 Celularity Inc. Treatment of lymphedema and related conditions using placental adherent cells
US20190167724A1 (en) * 2017-12-04 2019-06-06 Caire Medical-Biotechnology International Co. Neuroprotective composition, preparation process thereof and medical uses thereof
US20210315940A1 (en) * 2018-09-05 2021-10-14 Children's Medical Center Corporation Use of mesenchymal stromal cell exosomes in antenatal therapy
US10881693B2 (en) 2019-04-09 2021-01-05 Combangio, Inc. Processes for making and using a mesenchymal stem cell derived secretome
CN115707772A (zh) * 2021-08-18 2023-02-21 澳门大学 一种诱导剂、巨噬细胞及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1831356T3 (pl) * 2004-12-23 2017-07-31 DePuy Synthes Products, Inc. Komórki poporodowe pochodzące z tkanki pępowinowej i sposoby ich wytwarzania i stosowania
PT2366775E (pt) * 2006-03-23 2015-07-20 Pluristem Ltd Métodos para expansão celular e usos de células e de meios condicionados produzidos através deles para terapia
CN101657206B (zh) * 2007-02-12 2013-07-03 人类起源公司 利用胎盘干细胞治疗炎性疾病
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media

Also Published As

Publication number Publication date
CA2859768C (en) 2021-12-07
ES2606297T3 (es) 2017-03-23
US20170216366A1 (en) 2017-08-03
HRP20161601T1 (hr) 2017-05-19
JP2015502977A (ja) 2015-01-29
US10413573B2 (en) 2019-09-17
PT2793929T (pt) 2016-12-13
SI2793929T1 (sl) 2017-03-31
EP2793929B1 (en) 2016-09-14
DK2793929T3 (da) 2017-01-02
ITTO20111183A1 (it) 2013-06-22
CA2859768A1 (en) 2013-06-27
EP2793929A1 (en) 2014-10-29
WO2013093878A1 (en) 2013-06-27
HUE032489T2 (en) 2017-09-28
US20150017122A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
PL2793929T3 (pl) Podłoże kondycjonowane uzyskane z łożyskowych mezenchymalnych komórek macierzystych w terapii stanu przedrzucawkowego
IL286921A (en) Pertuzumab and Trastuzumab for use in treatment
HK1249548A1 (zh) 用於無脈絡膜的基因療法的aav載體
PL2903624T3 (pl) Pożywka kondycjonowana przez łożyskowe mezenchymalne komórki macierzyste z łożyska kobiety dotkniętej stanem przedrzucawkowym do stosowania w leczeniu nowotworu
IL232256A0 (en) Purine derivatives and their use in the treatment of diseases
EP2714059A4 (en) PAIN TREATMENT USING STAINCELLS FROM THE PLAZENTA
EP2821481A4 (en) CULTURE MEDIUM FOR THE MANUFACTURE OF NEURAL STEM CELLS AND USE THEREOF
PT2611906T (pt) Terapias sistémicas com células estaminais alogénicas para tratamento de doenças em gatos e cães
HK1248709A1 (zh) 氨基糖苷及其在治療遺傳性疾病中的用途
EP2861238A4 (en) OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
HK1198133A1 (en) Crizotinib for use in the treatment of cancer
PL2510085T3 (pl) Podłoże kondycjonowane komórkami macierzystymi od osób dorosłych do zastosowania w terapeutycznym leczeniu chorób nowotworowych
GB201120993D0 (en) Novel compounds and their use in therapy
IL229474A0 (en) Cannabinoids for use in the treatment of neuropathic pain
HK1172247A1 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
PL2683826T3 (pl) Zastosowanie aptamerów w terapii i/lub diagnostyce chorób autoimmunologicznych
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
EP2817304A4 (en) NOVEL COMPOUNDS AND THEIR THERAPEUTIC USE
EP2825194A4 (en) USE OF ANTITHROMBINE IN THE TREATMENT OF PRE-ECLAMPSIA
IL237411A0 (en) A method for diagnosing and treating cancer that targets molecules expressed in cancer stem cells
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
EP2911748A4 (en) CANCER STEM CELL VACCINATION AND TREATMENT
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
HUE038120T2 (hu) Transzferrin autoimmun betegségek kezelésében és/vagy megelõzésében történõ alkalmazásra